SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that its tests for Zika virus, tuberculosis, and other diseases will be presented this week at the 35th annual International Fair of Havana (FIHAV) at the EXPOCUBA fairground in Havana, Cuba.

According to the conference website, FIHAV is the most important multi-sector trade fair in Cuba, and is considered among the most representative of the markets in Latin America and the Caribbean. The 2017 conference will be held from October 30 to November 4, and in 2016 participation included 3,800 foreign exhibitors from 73 countries, 25 official delegations from various countries and 85 Chambers of Commerce and organizations promoting trade and investment, and around 150,000 professional visitors. A licensee of Co-Diagnostics products will be presenting in a booth to offer diagnostic solutions to the challenges presented by tropical diseases and other viruses.

Co-Diagnostics CEO Dwight Egan commented: “It is an incredible opportunity for Co-Diagnostics tests to be presented to a country that plays such an important role in the Caribbean region. With a population of over 11 million, an internationally respected biotechnology industry, an emphasis on preventive medicine, but a system in need of access to affordable, contemporary diagnostics, Cuba also represents a significant market for our products.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer:

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171031005752/en/

Co-Diagnostics
Andrew Benson, Investor Relations
801-438-1036
investors@codiagnostics.com